Targeted Oncology· @TargetedOnc · X·· 15 hours agoScore70
Body · original
DeLLphi-305 shows striking OS benefit with tarlatamab maintenance (HR 0.42).
Why wait until maintenance?
Could adding DLL3-directed therapy during induction chemoimmunotherapy improve outcomes further—or would overlapping toxicity outweigh the benefit?
#ESMO26
95 views · 0 likes · 0 reposts · 0 replies
Conference abstracts
LBA3matched by Presidential Symposium I
Tarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
https://esmocongress.esmo.orgSource: Targeted Oncology · x.com